Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).
She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.
§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts
§ 16 Grundlagen klinischer Arzneimittelprüfungen
§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023
§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)
Law firm of the year for IP Law
by Irina Rebin
Life Sciences Made in Europe – The European Commission’s Life Sciences Strategy 2030
by Irina Rebin
Adoption of Commission Implementing Regulation (EU) 2025/2086: New Rules on the Joint Clinical Assessment of Medical Devices and In Vitro Diagnostic Medical Devices
by Irina Rebin and Daniel Dietrich
by multiple authors
by Dr. Benedikt Groh and Fritz Krings
by Ross McNaughton and Oli Denne
by multiple authors
by Kathleen Munstermann-Senff, LL.M. (Medical Law) and Dr. Martin Jäger
by Dr. Julia Freifrau von Imhoff and Dr. Christian Frank, Licencié en droit (Paris II / Panthéon-Assas)
by multiple authors